Participation in another clinical study with an investigational product during the 21 days prior to first dose of olaparib and temozolomide
Concurrent enrollment in another clinical study or receipt of an investigational product within the last 4 weeks (participation in the survival follow-up period of a study is not an exclusion criterion)
Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment (i.e. D1 of cycle 1)
Participation in another clinical study with an investigational product during the last 30 days
Participation in another clinical study with an investigational product during the last 4 weeks.
Participation in another clinical study with an investigational product during the 4 weeks prior to therapy initiation
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product during the last 6 months
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product administered during the last 28 days.
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product during the last 4 weeks (prior use of bevacizumab in the upfront setting is allowed)
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product for cancer during the last 12 months
Participation in another clinical study with an investigational product during the last 6 months (mo)
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product during the last 3 months
Participation in another clinical study with an investigational product (IP) during the last 3 weeks before the first day of study treatment
Participation in another clinical study with an investigational product during the last 3 weeks
Participation in another clinical study with an investigational product during the last 4 weeks or 5 half-lives prior to starting on treatment.
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product during the last 21 days
Participation in another clinical study with receipt of an investigational product during the last 4 weeks
Concurrent enrollment in another therapeutic clinical study or receipt of an investigational product within the last 4 weeks (participation in the survival follow-up period of a study is not an exclusion criterion)
Participation in another clinical study with an investigational product during the last 14 days
Participation in another clinical study with receipt of an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product during the previous 4 weeks
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment (i.e., D1 of Cycle 1)
Participation in another clinical study with an investigational product during the last 14 days
Participation in another clinical study with an investigational product during the last 14 days
Participation in another clinical study with an investigational product during the last 21 days
